InProTher

InProTher is an early-stage biotechnology company. The company is targeting Human Endogenous Retroviruses (HERVs) for cancer treatment. HERVs are recognized as tumor-specific antigens, but so far, they have not been curable. InProTher uses advanced technology to target HERV tumor antigens, stimulating both arms of the immune system, humoral and cellular responses. The company delivers immunogens through the use of adenovirus and RNA vectors.